The song talks about a deep love that feels as if it has been there for a thousand years. The song in the movie talks about the love and romance between Bella and Edward who are the protagonists in the movie.
A Thousand Years Breaking Dawn Version 22
During the first century AD, Phoenix was mentioned 21 times by ten authors. From all these sources it appears that the myth of Phoenix originated in ancient Egyptian civilization and was later spoken of in Greek, Roman and Christian civilizations, respectively. Among the Egyptians, the myth of Phoenix was originally the myth of the sun rising again at dawn after each night, and the name of the city of Heliopolis in Herodotus must have been related to this. The Egyptians consider the phoenix a sacred bird, which is very rare. According to the people of Heliopolis, the phoenix appears in Egypt once every 500 years after the death of the previous phoenix. There are only a few pictures of this bird, and as can be seen from its shape and size in these pictures, the wings and jump are red and yellow are golden, and its general size is like an eagle. A strange story is told about the work of this bird, and that is that this bird brings its father's body, which is covered with a kind of fragrant plant gum, all the way from the Arab land to the Temple of the Sun and buries it there. It is said that in order to bring a corpse, first it makes a gum large enough to carry it, then it empties it and puts the corpse in it and closes its mouth with fresh gum, and then the bullet, which is correct. It has regained its original weight, is brought to Egypt, and while the entire surface of the bullet is covered with gum, it is placed inside the Temple of the Sun, as mentioned.In
Then I saw thrones, and seated on them were those to whom the authority to judge was committed. Also I saw the souls of those who had been beheaded for the testimony of Jesus and for the word of God, and those who had not worshiped the beast or its image and had not received its mark on their foreheads or their hands. They came to life and reigned with Christ for a thousand years. The rest of the dead did not come to life until the thousand years were ended. This is the first resurrection. Blessed and holy is the one who shares in the first resurrection! Over such the second death has no power, but they will be priests of God and of Christ, and they will reign with him for a thousand years.
Then I saw thrones, and seated on them were those to whom the authority to judge was committed. Also I saw the souls of those who had been beheaded for the testimony of Jesus and for the word of God, and those who had not worshiped the beast or its image and had not received its mark on their foreheads or their hands. They came to life and reigned with Christ for a thousand years.
And he seized the dragon, that ancient serpent, who is the devil and Satan, and bound him for a thousand years, and threw him into the pit, and shut it and sealed it over him, so that he might not deceive the nations any longer, until the thousand years were ended. After that he must be released for a little while. Then I saw thrones, and seated on them were those to whom the authority to judge was committed. Also I saw the souls of those who had been beheaded for the testimony of Jesus and for the word of God, and those who had not worshiped the beast or its image and had not received its mark on their foreheads or their hands. They came to life and reigned with Christ for a thousand years. The rest of the dead did not come to life until the thousand years were ended. This is the first resurrection.
At this point let me take a brief diversion into the evils of the US Securities and Exchange Commission (SEC). How is it that I knew about and had the chance to invest in Oisin Biotechnology and you didn't? Simply because I'm close enough to being an insider in this community to get an invite. The rules put in place on early stage investment essentially act to forbid what is called general solicitation: an early stage startup company can't simply advertise for investors. The founders can't reach out to the community at large. Raising a round cannot be public. The only only people normally allowed to invest in startups are those in the upper 5-10% of income or net worth, and the exceptions to that rule needed for seed and friends and family rounds, consisting of people of modest means like myself, to exist at all again require refraining from general solicitation. This is a great example of regulatory capture at work. The rules, ostensibly to protect people from themselves, as heaven forbid anyone actually be trusted to make their own assessments of risk in this world, are absolutely and definitely shaped over the years for far less altruistic reasons. The goal is to restrict the opportunity to invest in high-risk, high-reward early stage companies to established networks of professionals, to build barriers and keep out anyone not on the inside.
David Spiegel: Yes, it is a good question. So, it is a very difficult molecule to make. Well, two issues: first it is very difficult molecule to make, but also it is actually a difficult molecule to isolate. So even though it is found in all of us, it is found in our tissues, our bones, trying to isolate it in a pure form from the human body is incredibly difficult. Only very small quantities are obtained, and the compounds isolated are actually mixtures of very similar stereoisomers, a kind of different versions of glucosepane that simply can't be separated. So from my perspective I thought it would be quite valuable to take on this challenge, and that is really one of the main areas of focus for my laboratory, which is making very difficult molecules using techniques in organic chemistry. So in my mind, this is something that believed in for a long time. For glucosepane, it is a perfect marriage of interesting chemistry and incredibly interesting biology. The biology here is hard, and people have had a hard time, as you said, studying glucosepane, and of course making it has proven an incredibly difficult challenge because of its complex and intricate chemical structure. So we've been very interested in making it, and now we're in the phase of seeing what we can do with it, particularly with the goal of breaking glucosepane, or developing agents that can break glucosepane, that we think can actually reverse the pathology associated with aging.
David Spiegel: That's a good question. I think that from the standpoint of basic research, we've already made some progress in identifying some potential strategies for breaking glucosepane. As you know, there is a significant regulatory challenge associated with bringing new therapeutics to market, and so if I had to estimate - well, this is a very high bar in terms of ... well it is an extraordinary challenge, just the idea of making therapeutics that can break a molecule is kind of an untested concept. But the progress we are making, and the surge of interest right now in protein and enzyme-based therapeutics in pharma, makes me speculate that it is possible we could have something that is therapeutically viable on the order of 10-20 years from now. That may not seem like a short time, but from a therapeutics perspective, I think it is within our kind of vision.
Laron Syndrome was first identified in 1950 and there are only 350 people with it in the world, all descended from a single ancestor who introduced the mutated gene thousands of years ago. A third of them live in isolated communities in Ecuador, while others live in Spain. Unlike others with dwarfism, Laron patients don't lack growth hormone, but they have a defect in the receptor in the liver that is supposed to bind to the hormone and produce a substance called insulin-like growth factor 1. In Laron, there is no binding and no IGF-1 - and stunted growth as a result. But the absence of IGF-1 may also prevent the uncontrolled growth of cells that turn into cancer, and it creates extra sensitivity to insulin that serves as a shield against diabetes.
Biomarkers of aging of this sort are important as an independent measure of the degree to which a putative rejuvenation therapy is actually working, a test that can be carried out much more rapidly and cheaply than the only currently viable approach of life span studies. By "actually working" I mean not just clearing senescent cells, or breaking cross-links, or replacing stem cells, all of which are simple enough to verify in and of themselves given the technology to build the treatment in the first place, but that a successful implementation of such as therapy also has an impact on global measures that are (a) strongly associated with aging, and (b) sensitive enough to pick up a change in biological age corresponding to a few years of normal aging.
Naked mole-rats are very long-lived in comparison to near relative species, and have a great resistance to cancer - to the point at which researchers have not characterized and reported on any incidence of cancer in their laboratory colonies, now numbering thousands of individuals, and not for lack of searching. This is a far cry from similarly-sized rodent species, all of which have a very high rate of cancer. There has been considerable interest in the research community in recent years in identifying the underlying mechanisms of cancer resistance in naked mole-rats, with an eye to seeing whether or not they can form the basis for human therapies or enhancements. 2ff7e9595c
Comments